Product News from the 03/24/06 News Brief

Share this article:
Sanofi-Aventis announced that the FDA has approved the supplemental new drug application (sNDA) for Taxotere (docetaxel) injection concentrate in combination with cisplatin and 5-fluorouracil for the treatment of patients with advanced stomach (gastric) cancer, including cancer of the gastroesophageal (GE) junction, who have not received prior chemotherapy for advanced disease. Chiron said it is recalling and withdrawing its measles, mumps and rubella vaccine Morupar, distributed to developing countries in 2005, due to a slightly higher rate of adverse effects than in similar vaccines. Barr Pharmaceuticals said the FDA will not need to produce additional clinical data to support approval of its extended-cycle contraceptive Seasonique. In August the FDA said the drug could be approved but requested additional data to support Seasonique’s unique dosing regimen. Barr said it will continue to work with the FDA to resolve outstanding issues, including product labeling and post-marketing commitments.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.